||Vial: MOD GRF 1-29 ( CJC without DAC) . Ampoule: 2ml Sterile water for injection.
||Intramuscular or Subcutaneous injection.
||Store at room temperature away from heat and direct sunlight pre reconstitution. Refrigerate between 2-8’C post Reconstitution.
||Adult: SC Growth hormone deficiency Initial: 2 mcg/kg/ thrice a day. May increase dose gradually. Max: 10 mcg/kg/ Thrice a day.
||Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or preproliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment.
||Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumour growth. Monitoring in patients with scoliosis is recommended due to risk of progression of scoliosis.
|Adverse Drug Reactions
||Water retention, tingling, numbness and decreased insulin can be associated with use of CJC 1295. Also noted is tiredness, feeling of lethargy, head rush or euphoria, itching. Loss of glycaemic control in diabetics.
||High doses of corticosteroid may inhibit growth-promoting effects of HGH
|Pregnancy Category (US FDA)
||Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1sttrimester (and there is no evidence of a risk in later trimesters).